Imunon (IMNN) Cash & Equivalents (2010 - 2026)

Imunon (IMNN) has 17 years of Cash & Equivalents data on file, last reported at $4.8 million in Q1 2026.

• Quarterly Cash & Equivalents rose 66.94% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (up 66.94% YoY) and the FY2025 annual result came in at $8.8 million, up 49.52% from the prior year.
• Cash & Equivalents declined to $4.8 million in Q1 2026, from $8.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $28.4 million in Q1 2022 to a low of $2.3 million in Q1 2024.
• A 5-year average of $10.6 million and a median of $6.2 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 77.43% — and 2026, when it jumped 66.94%.
• Tracing IMNN's Cash & Equivalents over 5 years: stood at $11.5 million in 2022, then slumped by 49.2% to $5.8 million in 2023, then climbed by 0.59% to $5.9 million in 2024, then jumped by 49.52% to $8.8 million in 2025, then tumbled by 45.4% to $4.8 million in 2026.
• The last three Cash & Equivalents figures came in at $4.8 million (Q1 2026), $8.8 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.